These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2682 related items for PubMed ID: 20089952

  • 21. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group.
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [Abstract] [Full Text] [Related]

  • 22. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
    Széplaki G, Merkely B.
    Ideggyogy Sz; 2012 Nov 30; 65(11-12):369-76. PubMed ID: 23289171
    [Abstract] [Full Text] [Related]

  • 23. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
    Montalban X, Comi G, O'Connor P, Gold S, de Vera A, Eckert B, Kappos L.
    Mult Scler; 2011 Nov 30; 17(11):1341-50. PubMed ID: 21727148
    [Abstract] [Full Text] [Related]

  • 24. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CONFIRM Study Investigators.
    N Engl J Med; 2012 Sep 20; 367(12):1087-97. PubMed ID: 22992072
    [Abstract] [Full Text] [Related]

  • 25. Oral therapy for multiple sclerosis--sea change or incremental step?
    Carroll WM.
    N Engl J Med; 2010 Feb 04; 362(5):456-8. PubMed ID: 20089958
    [No Abstract] [Full Text] [Related]

  • 26. Placebo-controlled trial of oral laquinimod for multiple sclerosis.
    Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M, ALLEGRO Study Group.
    N Engl J Med; 2012 Mar 15; 366(11):1000-9. PubMed ID: 22417253
    [Abstract] [Full Text] [Related]

  • 27. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G, Filippi M, Wolinsky JS.
    Ann Neurol; 2001 Mar 15; 49(3):290-7. PubMed ID: 11261502
    [Abstract] [Full Text] [Related]

  • 28. Delayed fingolimod-associated asystole.
    Espinosa PS, Berger JR.
    Mult Scler; 2011 Nov 15; 17(11):1387-9. PubMed ID: 21652609
    [Abstract] [Full Text] [Related]

  • 29. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S, Baxter DC, Limone B, Roberts MS, Coleman CI.
    J Med Econ; 2012 Nov 15; 15(6):1088-96. PubMed ID: 22583065
    [Abstract] [Full Text] [Related]

  • 30. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 15; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 31. Fingolimod-associated macular edema: incidence, detection, and management.
    Jain N, Bhatti MT.
    Neurology; 2012 Feb 28; 78(9):672-80. PubMed ID: 22371414
    [Abstract] [Full Text] [Related]

  • 32. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
    Kappos L, O'Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, Ritter S, Schlosshauer R, von Rosenstiel P, Zhang-Auberson L, Francis G.
    Neurology; 2015 Apr 14; 84(15):1582-91. PubMed ID: 25795646
    [Abstract] [Full Text] [Related]

  • 33. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.
    Mult Scler; 2009 Aug 14; 15(8):965-76. PubMed ID: 19465443
    [Abstract] [Full Text] [Related]

  • 34. Safety and efficacy of reduced fingolimod dosage treatment.
    Yamout BI, Zeineddine MM, Sawaya RA, Khoury SJ.
    J Neuroimmunol; 2015 Aug 15; 285():13-5. PubMed ID: 26198913
    [Abstract] [Full Text] [Related]

  • 35. Fingolimod.
    Prescrire Int; 2011 Aug 15; 20(118):173-4, 176-7. PubMed ID: 21751747
    [Abstract] [Full Text] [Related]

  • 36. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH.
    Ann Neurol; 1996 Mar 15; 39(3):285-94. PubMed ID: 8602746
    [Abstract] [Full Text] [Related]

  • 37. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
    Arch Neurol; 2008 Feb 15; 65(2):199-204. PubMed ID: 18071030
    [Abstract] [Full Text] [Related]

  • 38. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Girard M, Pucci E, Iuliano G, Alroughani R, Oreja-Guevara C, Fernandez-Bolaños R, Grand'Maison F, Sola P, Spitaleri D, Granella F, Terzi M, Lechner-Scott J, Van Pesch V, Hupperts R, Sánchez-Menoyo JL, Hodgkinson S, Rozsa C, Verheul F, Butzkueven H, Kalincik T, MSBase Study Group.
    JAMA Neurol; 2015 Apr 15; 72(4):405-13. PubMed ID: 25665031
    [Abstract] [Full Text] [Related]

  • 39. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis.
    Barkhof F, de Jong R, Sfikas N, de Vera A, Francis G, Cohen J, TRANSFORMS study group.
    Mult Scler; 2014 Nov 15; 20(13):1704-13. PubMed ID: 24812043
    [Abstract] [Full Text] [Related]

  • 40. Fingolimod: a novel immunosuppressant for multiple sclerosis.
    Brown BA, Kantesaria PP, McDevitt LM.
    Ann Pharmacother; 2007 Oct 15; 41(10):1660-8. PubMed ID: 17785617
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 135.